FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887759512> ?p ?o ?g. }

• W2887759512 abstract "The aim of the current study was to identify a panel of cancer/testis antigens (CTAs) with the potential to be used as a complementary test to the prostate-specific antigen (PSA) test for prostate cancer (PCa) screening. PSA test is capable of identifying men under risk of PCa before the presence of symptoms. However, this screening has been considered a controversy assessment since many men presenting benign lesions (benign prostate hyperplasia or other inflammatory conditions) can also present increased PSA levels. Hence, the great current dilemma in PCa screening is to develop a test that in combination with PSA assay could present higher accuracy for PCa early diagnosis. CTAs constitute an important class of potential cancer biomarkers that are poorly studied in PCa. CTAs are normally expressed in testis and germ cells and are aberrantly over-expressed in cancers. This unique pattern of expression makes these genes potential candidates as specific tumor biomarkers. CTA aberrant expression in malignant tumors is associated with phenotypic changes that confer the cancer cells essential advantages for proliferation and survival. Our hypothesis is that a panel of CTAs differentially expressed in PCa compared to normal prostate tissue would be useful to develop a diagnostic biomarker panel to be used in combination with the PSA test. We initially evaluated the expression of 22 CTAs, using the Nanostring approach, in localized and metastatic PCa to identify those genes associated with more aggressive tumors. After validation by qRT-PCR, we verified that 8 genes were differentially expressed between indolent and aggressive tumors. Using immunohistochemistry and a quantitative image analysis to measure protein expression, we evaluated CTA protein levels in PCa and adjacent normal tissue paired samples. The CTAs CEP55, NUF2, PAGE4, PBK, RQCD1, SPAG4, SSX2 and TTK presented increased protein levels in PCa when compared to normal prostate tissue from the same patient. Increased levels of PAGE4, PBK, RQCD1, SPAG4 and SSX2 were more frequent among patients with Gleason Score 4+3 or higher. In an attempt to identify a panel of CTAs with increased expression in PCa vs. prostate normal samples, we used multiple logistic regression analysis (MLR). MLR analysis showed that a panel that includes all 8 CTAs analyzed correctly classified 88.9% of the cases (AUC=0.96; sensitivity=88.5%; specificity=89.2%). For the MLR analysis, we considered the intensity and the frequency of the cancer cells with positive CTA expression. The intensity of all 8 CTAs was significant in the analysis, while the frequency of staining was only relevant for NUF2, PBK, SSX2 and TTK. Our findings suggest that our 8 CTAs panel represent a potential biomarker with high accuracy to discriminate normal prostate from PCa. Further studies to evaluate their expression in bodily fluids will determine their potential as a non-invasive PCa screening test to be used in combination with PSA. Citation Format: Luciane T. Kagohara, Prakash Kulkarni, Takumi Shiraishi, Robert Vessella, Robert W. Veltri, Elana J. Fertig. Cancer/testis antigens: A biomarker panel for prostate cancer screening [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4525." @default.
• W2887759512 created "2018-08-22" @default.
• W2887759512 creator A5027701541 @default.
• W2887759512 creator A5041964655 @default.
• W2887759512 creator A5057037633 @default.
• W2887759512 creator A5064759824 @default.
• W2887759512 creator A5073431093 @default.
• W2887759512 creator A5083237199 @default.
• W2887759512 date "2018-07-01" @default.
• W2887759512 modified "2023-09-27" @default.
• W2887759512 title "Abstract 4525: Cancer/testis antigens: A biomarker panel for prostate cancer screening" @default.
• W2887759512 doi "https://doi.org/10.1158/1538-7445.am2018-4525" @default.
• W2887759512 hasPublicationYear "2018" @default.
• W2887759512 type Work @default.
• W2887759512 sameAs 2887759512 @default.
• W2887759512 citedByCount "0" @default.
• W2887759512 crossrefType "proceedings-article" @default.
• W2887759512 hasAuthorship W2887759512A5027701541 @default.
• W2887759512 hasAuthorship W2887759512A5041964655 @default.
• W2887759512 hasAuthorship W2887759512A5057037633 @default.
• W2887759512 hasAuthorship W2887759512A5064759824 @default.
• W2887759512 hasAuthorship W2887759512A5073431093 @default.
• W2887759512 hasAuthorship W2887759512A5083237199 @default.
• W2887759512 hasConcept C121608353 @default.
• W2887759512 hasConcept C126322002 @default.
• W2887759512 hasConcept C143998085 @default.
• W2887759512 hasConcept C147483822 @default.
• W2887759512 hasConcept C203014093 @default.
• W2887759512 hasConcept C2776235491 @default.
• W2887759512 hasConcept C2777562237 @default.
• W2887759512 hasConcept C2778042024 @default.
• W2887759512 hasConcept C2779134260 @default.
• W2887759512 hasConcept C2780192828 @default.
• W2887759512 hasConcept C2781197716 @default.
• W2887759512 hasConcept C2781406297 @default.
• W2887759512 hasConcept C3008058167 @default.
• W2887759512 hasConcept C502942594 @default.
• W2887759512 hasConcept C524204448 @default.
• W2887759512 hasConcept C55493867 @default.
• W2887759512 hasConcept C71924100 @default.
• W2887759512 hasConcept C86803240 @default.
• W2887759512 hasConcept C87874733 @default.
• W2887759512 hasConceptScore W2887759512C121608353 @default.
• W2887759512 hasConceptScore W2887759512C126322002 @default.
• W2887759512 hasConceptScore W2887759512C143998085 @default.
• W2887759512 hasConceptScore W2887759512C147483822 @default.
• W2887759512 hasConceptScore W2887759512C203014093 @default.
• W2887759512 hasConceptScore W2887759512C2776235491 @default.
• W2887759512 hasConceptScore W2887759512C2777562237 @default.
• W2887759512 hasConceptScore W2887759512C2778042024 @default.
• W2887759512 hasConceptScore W2887759512C2779134260 @default.
• W2887759512 hasConceptScore W2887759512C2780192828 @default.
• W2887759512 hasConceptScore W2887759512C2781197716 @default.
• W2887759512 hasConceptScore W2887759512C2781406297 @default.
• W2887759512 hasConceptScore W2887759512C3008058167 @default.
• W2887759512 hasConceptScore W2887759512C502942594 @default.
• W2887759512 hasConceptScore W2887759512C524204448 @default.
• W2887759512 hasConceptScore W2887759512C55493867 @default.
• W2887759512 hasConceptScore W2887759512C71924100 @default.
• W2887759512 hasConceptScore W2887759512C86803240 @default.
• W2887759512 hasConceptScore W2887759512C87874733 @default.
• W2887759512 hasLocation W28877595121 @default.
• W2887759512 hasOpenAccess W2887759512 @default.
• W2887759512 hasPrimaryLocation W28877595121 @default.
• W2887759512 hasRelatedWork W1969032819 @default.
• W2887759512 hasRelatedWork W1975990005 @default.
• W2887759512 hasRelatedWork W2047211736 @default.
• W2887759512 hasRelatedWork W2165907692 @default.
• W2887759512 hasRelatedWork W2465699166 @default.
• W2887759512 hasRelatedWork W2768989900 @default.
• W2887759512 hasRelatedWork W2887759512 @default.
• W2887759512 hasRelatedWork W2948859493 @default.
• W2887759512 hasRelatedWork W3132933772 @default.
• W2887759512 hasRelatedWork W2187289503 @default.
• W2887759512 isParatext "false" @default.
• W2887759512 isRetracted "false" @default.
• W2887759512 magId "2887759512" @default.
• W2887759512 workType "article" @default.